Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06123026 · ClinicalTrials.gov registry record · Phase 4
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
A Phase 4 study of Lactation Suppressed and Second Trimester Abortion, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06123026 is a Phase 4 study of Lactation Suppressed and Second Trimester Abortion that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06123026, a Phase 4 study of Lactation Suppressed and Second Trimester Abortion, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabergoline
Study Locations (1)
Illinois
- Northwestern Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06123026
The ClinicalTrials.gov registry entry for NCT06123026 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lactation Suppressed appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06123026 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06123026 about?
NCT06123026 is a clinical study titled "Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion". The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet a...
What is the current status of trial NCT06123026?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2023-12-18. Estimated completion is 2024-06-30.
What conditions does trial NCT06123026 study?
This clinical trial studies the following conditions: Lactation Suppressed, Second Trimester Abortion.
What interventions are being tested in trial NCT06123026?
The interventions under investigation include: Placebo (DRUG), Cabergoline (DRUG).
Who is sponsoring clinical trial NCT06123026?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06123026 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lactation Suppressed
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.